Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00031148 · ClinicalTrials.gov registry record · Phase 1
Keratinocyte Growth Factor to Prevent Acute GVHD
A Phase 1 study, sponsored by FDA Office of Orphan Products Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT00031148: Completed Phase 1 study, sponsored by FDA Office of Orphan Products Development.
NCT00031148 is a Phase 1 study that has completed, run by FDA Office of Orphan Products Development. The registered enrollment target is 72 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00031148, a Phase 1 study, has completed, sponsored by FDA Office of Orphan Products Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
This is a study to determine the safety and efficacy of keratinocyte growth factor (KGF) to prevent acute graft-versus-host disease (GVHD) in patients undergoing allogeneic bone marrow (BM) or peripheral blood progenitor cell (PBPC) transplantation.
Interventions
- DRUG Recombinant Human Keratinocyte Growth Factor (rHuKGF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2001-09 |
| Est. Completion | 2003-08 |
| Phase | Phase 1 |
What the finished NCT00031148 record still lists
NCT00031148 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% higher).
The record links to 0 conditions, and to 1 intervention - of which Recombinant Human Keratinocyte Growth Factor (rHuKGF) is the first listed.
NCT00031148 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00031148 about?
NCT00031148 is a clinical study titled "Keratinocyte Growth Factor to Prevent Acute GVHD". This is a study to determine the safety and efficacy of keratinocyte growth factor (KGF) to prevent acute graft-versus-host disease (GVHD) in patients undergoing allogeneic bone marrow (BM) or peripheral blood progenitor cell (PBPC) transplantation.
What is the current status of trial NCT00031148?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2001-09. Estimated completion is 2003-08.
What interventions are being tested in trial NCT00031148?
The interventions under investigation include: Recombinant Human Keratinocyte Growth Factor (rHuKGF) (DRUG).
Who is sponsoring clinical trial NCT00031148?
This trial is sponsored by FDA Office of Orphan Products Development, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00031148's enrollment target sits among peer trials
72 736th of 2000 higher than 1,254 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia